These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36763285)

  • 21. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.
    Filtz A; Carandina A; Fasiello A; Barbetta L; Lombardi R; Cinque F; Rizzi G; Ceriani E; Furlan L; Bellocchi C; Fracanzani AL; Hu C; Cogliati C; Canetta C; Peyvandi F; Montano N; Tobaldini E
    Intern Emerg Med; 2023 Mar; 18(2):359-366. PubMed ID: 36539604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remdesivir Use in the Real-World Setting: An Overview of Available Evidence.
    Akinosoglou K; Rigopoulos EA; Schinas G; Kaiafa G; Polyzou E; Tsoupra S; Tzouvelekis A; Gogos C; Savopoulos C
    Viruses; 2023 May; 15(5):. PubMed ID: 37243253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Off-Target
    Xu Y; Barauskas O; Kim C; Babusis D; Murakami E; Kornyeyev D; Lee G; Stepan G; Perron M; Bannister R; Schultz BE; Sakowicz R; Porter D; Cihlar T; Feng JY
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of whole genome sequencing to identify low-frequency mutations in SARS-CoV-2 patients treated with remdesivir.
    Nirmalarajah K; Yim W; Aftanas P; Li AX; Shigayeva A; Yip L; Zhong Z; McGeer AJ; Maguire F; Mubareka S; Kozak R
    Influenza Other Respir Viruses; 2023 Sep; 17(9):e13179. PubMed ID: 37752062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
    Coelho L; Falcão F; Póvoa P; Viegas E; Martins AP; Carmo E; Fonseca C; Campos L; Mansinho K; Carmo I; Soares J; Solano M; Mendes D; Miranda AC; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Sci Rep; 2023 Mar; 13(1):4482. PubMed ID: 36934143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The COVID-19 Pandemic as an Opportunity and Challenge for Registries in Health Services Research: Lessons Learned from the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS)].
    Pilgram L; Schons M; Jakob CEM; Claßen AY; Franke B; Tscharntke L; Schulze N; Fuhrmann S; Sauer G; de Miranda SMN; Prasser F; Stecher M; Vehreschild JJ
    Gesundheitswesen; 2021 Nov; 83(S 01):S45-S53. PubMed ID: 34731893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality).
    Pilgram L; Eberwein L; Jensen BO; Jakob CEM; Koehler FC; Hower M; Kielstein JT; Stecher M; Hohenstein B; Prasser F; Westhoff T; de Miranda SMN; Vehreschild MJGT; Lanznaster J; Dolff S;
    Infection; 2023 Feb; 51(1):71-81. PubMed ID: 35486356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program.
    Chan-Tack K; Sampson M; Earp J; Arya V; Yao L; Alexander J; Hausman E; Belew Y; Birnkrant D; Struble K
    J Clin Pharmacol; 2023 Feb; 63(2):259-265. PubMed ID: 36149807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.
    Martinez DR; Schäfer A; Leist SR; Li D; Gully K; Yount B; Feng JY; Bunyan E; Porter DP; Cihlar T; Montgomery SA; Haynes BF; Baric RS; Nussenzweig MC; Sheahan TP
    Cell Rep; 2021 Jul; 36(4):109450. PubMed ID: 34289384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
    Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
    Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study.
    Vicente-Valor J; Rodríguez-González C; Ferris-Villanueva M; Chamorro-de-Vega E; Romero-Jiménez R; Gómez-Costas D; Herrero-Bermejo S; Tejerina-Picado F; Osorio-Prendes S; Oarbeascoa-Royuela G; Herranz-Alonso A; Sanjurjo-Sáez M
    Pharmacol Rep; 2023 Oct; 75(5):1254-1264. PubMed ID: 37656351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease.
    Pilgram L; Eberwein L; Wille K; Koehler FC; Stecher M; Rieg S; Kielstein JT; Jakob CEM; Rüthrich M; Burst V; Prasser F; Borgmann S; Müller RU; Lanznaster J; Isberner N; Tometten L; Dolff S;
    Infection; 2021 Aug; 49(4):725-737. PubMed ID: 33851328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
    Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
    Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS).
    Kleineberg NN; Knauss S; Gülke E; Pinnschmidt HO; Jakob CEM; Lingor P; Hellwig K; Berthele A; Höglinger G; Fink GR; Endres M; Gerloff C; Klein C; Stecher M; Classen AY; Rieg S; Borgmann S; Hanses F; Rüthrich MM; Hower M; Tometten L; Haselberger M; Piepel C; Merle U; Dolff S; Degenhardt C; Jensen BO; Vehreschild MJGT; Erber J; Franke C; Warnke C;
    Eur J Neurol; 2021 Dec; 28(12):3925-3937. PubMed ID: 34411383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study.
    Miyazaki M; Yanagida R; Nakashima A; Matsuo K; Moriwaki N; Uchiyama M; Yamada Y; Hirata H; Kushima H; Kinoshita Y; Ishii H; Imakyure O
    Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 36013474
    [No Abstract]   [Full Text] [Related]  

  • 40. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
    Pruijssers AJ; George AS; Schäfer A; Leist SR; Gralinksi LE; Dinnon KH; Yount BL; Agostini ML; Stevens LJ; Chappell JD; Lu X; Hughes TM; Gully K; Martinez DR; Brown AJ; Graham RL; Perry JK; Du Pont V; Pitts J; Ma B; Babusis D; Murakami E; Feng JY; Bilello JP; Porter DP; Cihlar T; Baric RS; Denison MR; Sheahan TP
    Cell Rep; 2020 Jul; 32(3):107940. PubMed ID: 32668216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.